Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
568日前
Malaysia Bourse May Extend Thursday's Losses
The Malaysia stock market on Thursday halted the seven-day wining streak in which it had gained almost 60 points or 4 percent. The Kuala Lumpur Composite Index now sits just above the 1,580-point plateau and it may inch lower again on Friday.
RTTNews
|
30分前
Japan Shares May Tick Lower Again On Friday
The Japan stock market on Thursday snapped the six-day winning streak in which it had surged more than 3,000 points or 7.3 percent. The Nikkei 225 now sits just beneath the 42,650-point plateau and it may remain stuck in neutral on Friday.
RTTNews
|
1時0分前
New Zealand Manufacturing Sector Expands In July - BusinessNZ
The manufacturing sector in New Zealand moved up into expansion territory in July, BusinessNZ said on Friday with a seasonally adjusted Performance of Manufacturing Index score of 52.8.
RTTNews
|
1時7分前
Japan GDP Data Due On Friday
Japan will on Friday release preliminary Q2 numbers for gross domestic product, highlighting a busy day for Asia-Pacific economic activity. GDP is expected to rise 0.1 percent on quarter and 0.4 percent on year following the flat quarterly reading and the 0.2 percent contraction in the three months prior. Capex is seen higher by 0.5 percent on quarter, easing from 1.1 percent in Q1.
RTTNews
|
2時0分前
U.S. Dollar Firms After Strong PPI Data
The U.S. dollar climbed against its major counterparts in the New York session on Thursday, following the release of hotter-than-expected producer inflation report for July.
RTTNews
|
2時10分前
Canadian Market Remains In Negative Territory After Weak Start
The Canadian market, which opened on a weak note Thursday morning, continues to languish in negative territory well past noon, weighed down by losses in technology and industrials sectors.
RTTNews
|
6時14分前
Swiss Market Ends Modestly Higher After Mild Struggle
The Switzerland market recovered after a flat start on Thursday, and after staying positive till well past noon, suffered a setback but regained some strength to eventually end the day's session modestly higher.
RTTNews
|
6時39分前
